25 patents
Utility
Ifetroban Treatment for Systemic Sclerosis
30 Nov 23
The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.
Leo PAVLIV, James West, Ines Macias-Perez, Erica Carrier
Filed: 10 Aug 23
Utility
Injectable ibuprofen formulation
7 Nov 23
The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition.
Leo Pavliv, Andrew Vila
Filed: 7 May 20
Utility
Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban
31 Aug 23
The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
Leo PAVLIV, Bryan VOSS, James West, Erica Carrier
Filed: 10 Apr 23
Utility
Thromboxane receptor antagonists in AERD/asthma
7 Feb 23
The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.
Leo Pavliv
Filed: 18 Nov 19
Utility
Injectable Solution of Norepinephrine
28 Jul 22
A ready-to-administer stable injectable norepinephrine solution comprising water, norepinephrine, and a tonicity agent.
Leo PAVLIV, Andrew VILA
Filed: 26 Jan 22
Utility
Thromboxane Receptor Antagonists in AERD/Asthma
14 Jul 22
The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.
Leo PAVLIV
Filed: 28 Mar 22
Utility
Ifetroban Treatment for Systemic Sclerosis
5 May 22
The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.
Leo PAVLIV, James West, Ines Macias-Perez, Erica Carrier
Filed: 14 Jan 22
Utility
Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban
13 May 21
The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
Leo PAVLIV, Bryan VOSS, James West, Erica Carrier
Filed: 17 Jan 21
Utility
Compositions and methods of treating cardiac fibrosis with ifetroban
23 Feb 21
The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
Leo Pavliv, Bryan Voss, James West, Erica Carrier
Filed: 27 Jan 20
Utility
Ifetroban Treatment for Systemic Sclerosis
21 Jan 21
The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.
Leo PAVLIV, James West, Ines Macias-Perez, Erica Carrier
Filed: 25 Sep 20
Utility
Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
2 Dec 20
The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.
Leo PAVLIV, Martin OGLETREE
Filed: 15 Jun 20
Utility
Stabilized Statin Formulations
7 Oct 20
The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.
Leo PAVLIV, Andrew Vila
Filed: 28 Jun 20
Utility
Doses and methods for administering telavancin
24 Aug 20
Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by Staphylococcus aureus, such as bacteremia, pneumonia, endocarditis, osteomyelitis, a prosthetic joint infection or a complicated skin and skin structure infection, are disclosed.
Steven L. Barriere, Arthur Lo, Mathai Mammen, Philip Worboys
Filed: 3 Apr 18
Utility
Injectable Ibuprofen Formulation
19 Aug 20
The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition.
Leo PAVLIV, Andrew VILA
Filed: 6 May 20
Utility
Ifetroban Treatment for Systemic Sclerosis
12 Aug 20
The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.
Leo Pavliv, James West, Ines Macias-Perez, Erica Carrier
Filed: 29 Apr 20
Utility
Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
3 Jun 20
The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.
Leo PAVLIV, Martin OGLETREE
Filed: 3 Feb 20
Utility
Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban
20 May 20
The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
Leo PAVLIV, Bryan VOSS, James West, Erica Carrier
Filed: 26 Jan 20
Utility
Thromboxane Receptor Antagonists in AERD/Asthma
20 May 20
The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.
Leo PAVLIV
Filed: 17 Nov 19
Utility
Acetylcysteine Compositions and Methods of use Thereof
22 Apr 20
A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed.
Leo Pavliv, Amy Rock
Filed: 17 Dec 19
Utility
Ifetroban Treatment for Systemic Sclerosis
15 Apr 20
The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.
Leo PAVLIV, James West, Ines Macias-Perez, Erica Carrier
Filed: 10 Dec 19